Chemotherapy Patients Should Exercise Caution in Taking Herbal Supplements

In our Frequently Asked Questions section, we previously addressed the question, “Can I take any nutritional supplements during chemotherapy?” by noting the potential beneficial and adverse effects that might arise from use of supplements, and by suggesting a candid discussion with treating physicians. However, the New York Attorney General recently noted that consumers of supplements have more than just medication interactions to be concerned about. Genetic testing of supplements sold at GNC, Target, Walgreens, and Walmart revealed that only 21% of supplements actually contained the herbal ingredient listed on the labels—at Walmart it was only 4%. Moreover, 35% of products tested contained DNA from plants not listed on the labels. Said Attorney General Schneiderman,

“The DNA test results seem to confirm long-standing questions about the herbal supplement industry. Mislabeling, contamination, and false advertising are illegal. They also pose unacceptable risks to New York families—especially those with allergies to hidden ingredients.”

These findings highlight an extraordinary lack of oversight in the supplement industry, which some manufacturers exploit routinely. We have therefore amended our FAQ section to include this potential concern, and we continue to advocate for open discussions between patients and physicians.

Palbociclib for Patients with Previously Treated Mantle Cell Lymphoma

Earlier this week the FDA granted accelerated approval to palbociclib for the treatment of advanced (metastatic) breast cancer in combination with letrozole. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby suppressing tumor cell proliferation.

Over the past decade, researchers at Weill Cornell have led investigations of palbociclib in multiple myeloma and mantle cell lymphoma, including an ongoing phase I trial of palbociclib in combination with ibrutinib for patients with previously treated mantle cell lymphoma. Additional trials are planned.

Please look to this space for further updates concerning palbociclib for lymphoma patients. A full listing of available clinical trials can be found on our clinical trials page.

Dr. Peter Martin Explains a Recently Opened Trial Testing the Combination of Azacitidine Plus R-CHOP

In his words, Dr. Peter Martin, explains a recently opened phase 1 trial testing the combination of azacitidine plus R-CHOP in patients with high risk previously untreated diffuse large B-cell lymphoma (DLBCL) or grade 3B follicular lymphoma.